Eli Lilly and Company has emerged as in the manufacturing of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant capacity to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide utilizes a series of precision steps to ensure